Literature DB >> 30456543

Antibody-initiated beneficial and harmful immune responses.

Arpad Zsigmond Barabas1, Chad Douglas Cole2, Rene Lafreniere3.   

Abstract

A critical function of the immune system is to maintain tolerance to self by corrective immune responses throughout life, including preventing or correcting changes that may interfere with organ function and architectural integrity. These changes have two broad categories, namely (1) exogenous antigen-induced mishaps (e.g., due to bacterial, viral or fungal infections) and (2) endogenous antigen-caused ailments initiated by modified self-antigens derived from damaged organs following exposure to smoke, certain drugs, chemicals, infectious agents, radiation, etc., resulting in autoimmune diseases or cancer. In some cases, cells of the immune system are unable to respond with a corrective antibody response. For example, presentation of a modified self-antigen can initiate a pathogenic IgG immune response, thereby causing an autoimmune disease. Furthermore, if cancer-associated antigens are not appropriately presented to the cells of the immune system, there is failure to mount a specific pathogenic lytic IgG autoantibody response for recognition and elimination of cancer-associated antigens, and as a consequence, the cancer continues to proliferate.The third vaccination technique that we have developed and designated a modified vaccination technique (MVT) is able to correct these immunological mishaps. The premise of the MVT is that it can prevent both exogenous (infectious and contagious diseases) and endogenous (autoimmune diseases and cancer) antigen-caused diseases, as well as terminate established diseases. Therefore, by exploiting the immune system's natural abilities to make corrective responses, it has both prophylactic and therapeutic actions, with minimal side effects.

Entities:  

Keywords:  Antibody-initiated beneficial; Harmful immune responses

Mesh:

Substances:

Year:  2018        PMID: 30456543     DOI: 10.1007/s12026-018-9037-0

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  35 in total

Review 1.  B-cell targeted therapies in human autoimmune diseases: an updated perspective.

Authors:  Michael J Townsend; John G Monroe; Andrew C Chan
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

Review 2.  Natural serum IgM maintains immunological homeostasis and prevents autoimmunity.

Authors:  Jessica J Manson; Claudia Mauri; Michael R Ehrenstein
Journal:  Springer Semin Immunopathol       Date:  2004-12-21

Review 3.  Monoclonal antibodies in treatment of multiple sclerosis.

Authors:  P S Rommer; A Dudesek; O Stüve; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

4.  Naturally occurring anti-tissue antibodies in rat sera.

Authors:  D M Weir; R N Pinckard; C J Elson; D E Suckling
Journal:  Clin Exp Immunol       Date:  1966-10       Impact factor: 4.330

Review 5.  Regaining tolerance to a self-antigen by the modified vaccination technique.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Rene Lafreniere; Donald Mackay Weir
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 6.  Design of effective immunotherapy for human autoimmunity.

Authors:  Marc Feldmann; Lawrence Steinman
Journal:  Nature       Date:  2005-06-02       Impact factor: 49.962

Review 7.  B cell targeted therapy in autoimmunity.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2007-03-27       Impact factor: 7.094

8.  Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease.

Authors:  B N Becker; H Fuchs; R Hakim
Journal:  J Am Soc Nephrol       Date:  1995-04       Impact factor: 10.121

9.  Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Biologics       Date:  2007-03

Review 10.  Preventing and treating chronic disorders using the modified vaccination technique.

Authors:  Arpad Zsigmond Barabas; Donald Mackay Weir; Chad Douglas Cole; Arpad David Barabas; Nizar Jacques Bahlis; Richard Milton Graeff; Rene Lafreniere
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  4 in total

1.  Editorial: autoimmunity-the ever endless world.

Authors:  Elias Toubi
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

2.  Exploration of the Immune-Related Long Noncoding RNA Prognostic Signature and Inflammatory Microenvironment for Cervical Cancer.

Authors:  Hui Yao; Xiya Jiang; Hengtao Fu; Yinting Yang; Qinqin Jin; Weiyu Zhang; Wujun Cao; Wei Gao; Senlin Wang; Yuting Zhu; Jie Ying; Lu Tian; Guo Chen; Zhuting Tong; Jian Qi; Shuguang Zhou
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

3.  Immune-Related Four-lncRNA Signature for Patients with Cervical Cancer.

Authors:  Jianfeng Zheng; Benben Cao; Xia Zhang; Zheng Niu; Jinyi Tong
Journal:  Biomed Res Int       Date:  2020-11-12       Impact factor: 3.411

4.  The Role of Autophagy in Tumor Immune Infiltration in Colorectal Cancer.

Authors:  Yu Bian-Fang; Wu Dong-Ning; Teng Dan; Shi Jian-Yu; Wang Shi-Yi; Wang Ben-Jun; Dong Xin; Zhao Wen-Wen; Wang Qing-Feng; Zhao Yan
Journal:  Anal Cell Pathol (Amst)       Date:  2022-03-14       Impact factor: 2.916

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.